Ipsen: Q1 sales up 9.6%

(CercleFinance.com) - Pharmaceutical group Ipsen has announced that it continued to post solid sales growth in Q1 2020, which reached 9.
6% at 654.6 million euros as reported, or 8.7% at constant exchange rates.

At constant exchange rates, specialty care products posted 12.5% growth, boosted by Somatuline, Cabometyx and Deceptyl, while family health posted a 21.9% fall, owing to the centralisation of hospital network purchases and the impact of Covid-19 in China.

Ipsen also says that it has suspended its financial targets for 2020 in the light of the pandemic, considering that, at this stage it is not possible to quantify the financial impact that the crisis will have on the group.


Copyright (c) 2020 CercleFinance.com. All rights reserved.